India Pre-Market Regulatory Roundup — October 30, 2026
The 50 filings from the October 29-30, 2026 overnight window are dominated by Q2 FY27 earnings releases and procedural notices, with a clear bifurcation between strong performers and stressed balance sheets. Deepak Nitrite delivered its highest-ever Q2 with total income up 61% YoY and EBITDA up 187% YoY, while V-Guard posted 38.2% revenue growth but a 325 bps gross margin contraction and sequential EBITDA margin decline. RPG Life Sciences crossed the ₹200 crore quarterly revenue milestone (+16.5% YoY) but saw consolidated profit fall 23.4% YoY on higher employee and other expenses. STL Networks returned to standalone profitability (₹5.10 Cr PAT vs a ₹12.24 Cr loss) yet consolidated net worth turned negative at ₹(58.41) Cr with DSCR and ISCR below 1.0. Praruh Technologies reported explosive H1 growth (revenue +378%, PAT +733%) but flagged H2 seasonality. Capital actions include a ₹1,180.17 lakh rights issue by Suvidhaa Infoserve, a QIP floor price of ₹127.01 by Manaksia Coated Metals, and interim dividends from Godrej Consumer (₹5/share) and Sanofi India (₹75/share). Thyrocare's shareholder approval of its NHL stake sale to Trovera drew 18.44% public institutional dissent, a governance signal worth monitoring. The dominant cross-cutting theme is margin pressure from input costs and product mix despite robust topline growth, alongside a heavy calendar of earnings calls and board meetings in early November.